{"filing":{"accession_number":"0001628280-26-053351","cik":"0001706431","ticker":"VIR","company_name":"Vir Biotechnology, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"vir-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/vir-20260805.htm"},"events":[{"id":25166,"run_id":22835,"accession_number":"0001628280-26-053351","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 5, 2026. The press release discloses financial results including total revenues of $238.9 million, R\u0026D expenses of $135.3 million, net income of $80.1 million ($0.48 per share), and cash position of $1.01 billion. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25920,"accession_number":"0001628280-26-053351","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 5, 2026. The press release discloses financial results including total revenues of $238.9 million, R\u0026D expenses of $135.3 million, net income of $80.1 million ($0.48 per share), and cash position of $1.01 billion. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:15:43.095938+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25920,"accession_number":"0001628280-26-053351","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 5, 2026. The press release discloses financial results including total revenues of $238.9 million, R\u0026D expenses of $135.3 million, net income of $80.1 million ($0.48 per share), and cash position of $1.01 billion. The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:15:43.095938+00:00","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-08-05"}]}